If left undiagnosed and untreated for a prolonged period, fatty liver disease can progress to more serious conditions, such as cirrhosis and liver cancer.
All over the United States, countless research projects designed to improve outcomes have lost funding or been shut down. Even screening efforts targeting patients in impoverished communities have been impacted by these policies.
The first 250 patients has been enrolled in the CORCINCH-HF U.S. pivotal trial evaluating the AccuCinch Transcatheter Left Ventricular Restoration System in patients with HFrEF.
"I wasn’t expecting these results among women in this lower age group, because we usually see increased risk for heart disease among older women," one cardiologist said. "It was definitely surprising.”
There were no statistical differences in overall complication rates between the traditional and expedited groups, but there were marked savings and shorter hospital stays.
The past four years have witnessed major advancements in medical science’s drive to unravel the complexities of the human immune system. We have the COVID-19 pandemic to thank for much of the progress.
